$32.78
1.073.37%
At close: -
$33.11
0.331.01%
After Hours: 5:54 PM EDT
Comments
Loading...
Ionis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IONS | Benzinga
Ionis Pharmaceuticals Inc has a consensus price target of $56.64 based on the ratings of 30 analysts. The high is $88 issued by Wells Fargo on May 4, 2023. The low is $27 issued by SVB Leerink on February 23, 2023. The 3 most-recent analyst ratings were released by Guggenheim, HC Wainwright & Co., and Needham on May 1, 2025, May 1, 2025, and April 30, 2025, respectively. With an average price target of $56.33 between Guggenheim, HC Wainwright & Co., and Needham, there's an implied 70.14% upside for Ionis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
HC Wainwright & Co.
Needham
Redburn Atlantic
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Ionis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/01/2025 | Buy Now | 93.3% | Guggenheim | Debjit Chattopadhyay52% | $65 → $64 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | 51.01% | HC Wainwright & Co. | Mitchell Kapoor45% | $45 → $50 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 66.11% | Needham | Joseph Stringer53% | $60 → $55 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | 35.91% | HC Wainwright & Co. | Mitchell Kapoor45% | → $45 | Initiates | → Buy | Get Alert |
| 04/03/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay52% | — | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | 17.79% | Redburn Atlantic | Joshua Smith 40% | → $39 | Initiates | → Neutral | Get Alert |
| 03/24/2025 | Buy Now | 35.91% | JP Morgan | Jessica Fye67% | $47 → $45 | Maintains | Neutral | Get Alert |
| 03/11/2025 | Buy Now | 41.95% | JP Morgan | Jessica Fye67% | $51 → $47 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 93.3% | Citigroup | David Lebowitz52% | $67 → $64 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | 111.42% | RBC Capital | Luca Issi41% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | 35.91% | BMO Capital | Kostas Biliouris33% | $60 → $45 | Maintains | Market Perform | Get Alert |
| 02/20/2025 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 111.42% | RBC Capital | Luca Issi41% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 87.25% | Piper Sandler | Allison Bratzel68% | $65 → $62 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 132.56% | Wells Fargo | Yanan Zhu39% | $82 → $77 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | 96.32% | Guggenheim | Debjit Chattopadhyay52% | $70 → $65 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | 111.42% | RBC Capital | Luca Issi41% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 08/26/2024 | Buy Now | 66.11% | JP Morgan | Jessica Fye67% | $50 → $55 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 111.42% | Guggenheim | Debjit Chattopadhyay52% | $64 → $70 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 11.75% | Goldman Sachs | Salveen Richter52% | $33 → $37 | Maintains | Sell | Get Alert |
| 08/02/2024 | Buy Now | 54.03% | Barclays | Gena Wang50% | $45 → $51 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 81.21% | BMO Capital | Kostas Biliouris33% | $67 → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 07/24/2024 | Buy Now | 87.25% | Leerink Partners | Mani Foroohar49% | $53 → $62 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/23/2024 | Buy Now | 78.19% | TD Cowen | Yaron Werber37% | $54 → $59 | Maintains | Buy | Get Alert |
| 07/23/2024 | Buy Now | 105.38% | B of A Securities | Jason Gerberry60% | $67 → $68 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | 102.36% | B of A Securities | Jason Gerberry60% | $64 → $67 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 126.52% | Jefferies | Akash Tewari45% | $29 → $75 | Upgrade | Underperform → Buy | Get Alert |
| 06/27/2024 | Buy Now | 60.07% | Stifel | Paul Matteis42% | $50 → $53 | Maintains | Hold | Get Alert |
| 06/14/2024 | Buy Now | — | Bernstein | William Pickering40% | — | Upgrade | Underperform → Market Perform | Get Alert |
| 06/03/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 147.66% | Wells Fargo | Yanan Zhu39% | $85 → $82 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Wolfe Research | Andy Chen43% | — | Upgrade | Peer Perform → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 126.52% | Oppenheimer | Jay Olson62% | $72 → $75 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | 117.46% | Oppenheimer | Jay Olson62% | $65 → $72 | Maintains | Outperform | Get Alert |
| 02/26/2024 | Buy Now | 96.32% | Oppenheimer | Jay Olson62% | $63 → $65 | Reinstates | → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | 90.27% | Piper Sandler | Do Kim54% | $62 → $63 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | 66.11% | JP Morgan | Jessica Fye67% | $52 → $55 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | 111.42% | RBC Capital | Luca Issi41% | $65 → $70 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | 87.25% | Piper Sandler | Do Kim54% | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | 87.25% | B of A Securities | Jason Gerberry60% | $52 → $62 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | 51.01% | Stifel | Paul Matteis42% | $45 → $50 | Maintains | Hold | Get Alert |
| 11/17/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -15.43% | Goldman Sachs | Salveen Richter52% | $25 → $28 | Maintains | Sell | Get Alert |
| 11/03/2023 | Buy Now | 44.97% | Morgan Stanley | Michael Ulz63% | $45 → $48 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | 57.05% | B of A Securities | Jason Gerberry60% | $33 → $52 | Upgrade | Underperform → Neutral | Get Alert |
| 10/05/2023 | Buy Now | 96.32% | RBC Capital | Luca Issi41% | → $65 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | 90.27% | Raymond James | — | → $63 | Initiates | → Strong Buy | Get Alert |
| 09/27/2023 | Buy Now | 35.91% | Morgan Stanley | Michael Ulz63% | $42 → $45 | Maintains | Equal-Weight | Get Alert |
| 09/27/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 81.21% | Citigroup | David Lebowitz52% | $36 → $60 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2023 | Buy Now | 75.17% | Piper Sandler | Do Kim54% | → $58 | Assumes | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 96.32% | RBC Capital | Luca Issi41% | → $65 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 8.73% | Citigroup | David Lebowitz52% | $30 → $36 | Upgrade | Sell → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 165.78% | Wells Fargo | Vanck Zhu75% | $92 → $88 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 11.75% | Barclays | Gena Wang50% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 26.85% | Morgan Stanley | Michael Ulz63% | $40 → $42 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | -6.37% | Bernstein | William Pickering40% | → $31 | Initiates | → Underperform | Get Alert |
| 02/23/2023 | Buy Now | -18.45% | SVB Leerink | Mani Foroohar49% | $34 → $27 | Maintains | Market Perform | Get Alert |
| 02/23/2023 | Buy Now | 96.32% | RBC Capital | Luca Issi41% | → $65 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | 102.36% | BMO Capital | Gary Nachman58% | $70 → $67 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 20.81% | Barclays | Gena Wang50% | $44 → $40 | Maintains | Equal-Weight | Get Alert |
| 02/23/2023 | Buy Now | 81.21% | Needham | Joseph Stringer53% | → $60 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 2.69% | SVB Leerink | Joseph Schwartz65% | $33 → $34 | Maintains | Market Perform | Get Alert |
| 01/23/2023 | Buy Now | -0.33% | SVB Leerink | Mani Foroohar49% | $32 → $33 | Maintains | Market Perform | Get Alert |
| 01/19/2023 | Buy Now | 87.25% | Piper Sandler | Do Kim54% | $60 → $62 | Maintains | Overweight | Get Alert |
| 12/21/2022 | Buy Now | 20.81% | Morgan Stanley | Michael Ulz63% | $56 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/10/2022 | Buy Now | 69.13% | Morgan Stanley | Andrew Galler33% | $57 → $56 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | -6.37% | Citigroup | David Lebowitz52% | $28 → $31 | Maintains | Sell | Get Alert |
| 11/10/2022 | Buy Now | -21.47% | SVB Leerink | Mani Foroohar49% | $30 → $26 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 72.15% | Morgan Stanley | Andrew Galler33% | $30 → $57 | Upgrade | Underweight → Overweight | Get Alert |
| 08/10/2022 | Buy Now | -15.43% | Citigroup | David Lebowitz52% | $26 → $28 | Maintains | Sell | Get Alert |
| 08/10/2022 | Buy Now | 93.3% | RBC Capital | Luca Issi41% | $67 → $64 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 75.17% | Piper Sandler | Do Kim54% | $55 → $58 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | 78.19% | Oppenheimer | Justin Kim38% | → $59 | Assumes | → Outperform | Get Alert |
| 06/21/2022 | Buy Now | -18.45% | SVB Leerink | Mani Foroohar49% | $26 → $27 | Maintains | Market Perform | Get Alert |
| 05/09/2022 | Buy Now | -9.39% | Morgan Stanley | David Lebowitz52% | $31 → $30 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for Ionis Pharmaceuticals (IONS) stock?
The latest price target for Ionis Pharmaceuticals (NASDAQ:IONS) was reported by Guggenheim on May 1, 2025. The analyst firm set a price target for $64.00 expecting IONS to rise to within 12 months (a possible 93.30% upside). 38 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ionis Pharmaceuticals (IONS)?
The latest analyst rating for Ionis Pharmaceuticals (NASDAQ:IONS) was provided by Guggenheim, and Ionis Pharmaceuticals maintained their buy rating.
When was the last upgrade for Ionis Pharmaceuticals (IONS)?
The last upgrade for Ionis Pharmaceuticals Inc happened on July 24, 2024 when Leerink Partners raised their price target to $62. Leerink Partners previously had a market perform for Ionis Pharmaceuticals Inc.
When was the last downgrade for Ionis Pharmaceuticals (IONS)?
The last downgrade for Ionis Pharmaceuticals Inc happened on August 2, 2024 when BMO Capital changed their price target from $67 to $60 for Ionis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ionis Pharmaceuticals (IONS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on May 1, 2025 so you should expect the next rating to be made available sometime around May 1, 2026.
Is the Analyst Rating Ionis Pharmaceuticals (IONS) correct?
While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a maintained with a price target of $65.00 to $64.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $33.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
